Genertec Universal Medical Group Company Limited (5UM) - Net Assets
Based on the latest financial reports, Genertec Universal Medical Group Company Limited (5UM) has net assets worth €25.04 Billion EUR (≈ $29.27 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€84.32 Billion ≈ $98.58 Billion USD) and total liabilities (€59.28 Billion ≈ $69.30 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 5UM goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €25.04 Billion |
| % of Total Assets | 29.7% |
| Annual Growth Rate | 16.02% |
| 5-Year Change | 42.08% |
| 10-Year Change | N/A |
| Growth Volatility | 10.25 |
Genertec Universal Medical Group Company Limited - Net Assets Trend (2016–2025)
This chart illustrates how Genertec Universal Medical Group Company Limited's net assets have evolved over time, based on quarterly financial data. See 5UM cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Genertec Universal Medical Group Company Limited (2016–2025)
The table below shows the annual net assets of Genertec Universal Medical Group Company Limited from 2016 to 2025. For live valuation and market cap data, see market value of Genertec Universal Medical Group Company.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €25.04 Billion ≈ $29.27 Billion |
+9.49% |
| 2024-12-31 | €22.87 Billion ≈ $26.74 Billion |
+12.28% |
| 2023-12-31 | €20.37 Billion ≈ $23.81 Billion |
+3.37% |
| 2022-12-31 | €19.70 Billion ≈ $23.03 Billion |
+11.80% |
| 2021-12-31 | €17.62 Billion ≈ $20.60 Billion |
+17.76% |
| 2020-12-31 | €14.97 Billion ≈ $17.50 Billion |
+11.29% |
| 2019-12-31 | €13.45 Billion ≈ $15.72 Billion |
+31.11% |
| 2018-12-31 | €10.26 Billion ≈ $11.99 Billion |
+37.33% |
| 2017-12-31 | €7.47 Billion ≈ $8.73 Billion |
+13.60% |
| 2016-12-31 | €6.57 Billion ≈ $7.69 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Genertec Universal Medical Group Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 409.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €11.13 Billion | 53.13% |
| Other Components | €9.82 Billion | 46.87% |
| Total Equity | €20.94 Billion | 100.00% |
Genertec Universal Medical Group Company Limited Competitors by Market Cap
The table below lists competitors of Genertec Universal Medical Group Company Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Everi Holdings Inc
NYSE:EVRI
|
$1.24 Billion |
|
Playtika Holding Corp
NASDAQ:PLTK
|
$1.24 Billion |
|
Jiangxi Guotai Civilian
SHG:603977
|
$1.24 Billion |
|
Guizhou Qianyuan Power Co Ltd
SHE:002039
|
$1.24 Billion |
|
Qingdao Haier Biomedical Co Ltd
SHG:688139
|
$1.24 Billion |
|
Generation Capital Ltd
TA:GNRS
|
$1.23 Billion |
|
Jiangsu Bojun Industrial Technology Co. Ltd
SHE:300926
|
$1.23 Billion |
|
Zhejiang Chunhui Intelligent Control Co. Ltd.
SHE:300943
|
$1.23 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genertec Universal Medical Group Company Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 18,853,737,000 to 20,942,871,000, a change of 2,089,134,000 (11.1%).
- Net income of 2,208,951,000 contributed positively to equity growth.
- Dividend payments of 615,496,000 reduced retained earnings.
- Other factors increased equity by 495,679,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.21 Billion | +10.55% |
| Dividends Paid | €615.50 Million | -2.94% |
| Other Changes | €495.68 Million | +2.37% |
| Total Change | €- | 11.08% |
Book Value vs Market Value Analysis
This analysis compares Genertec Universal Medical Group Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.05x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €4.35 | €0.53 | x |
| 2018-12-31 | €5.85 | €0.53 | x |
| 2019-12-31 | €6.49 | €0.53 | x |
| 2020-12-31 | €7.24 | €0.53 | x |
| 2021-12-31 | €7.81 | €0.53 | x |
| 2022-12-31 | €8.26 | €0.53 | x |
| 2023-12-31 | €9.17 | €0.53 | x |
| 2024-12-31 | €9.97 | €0.53 | x |
| 2025-12-31 | €10.40 | €0.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genertec Universal Medical Group Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.55%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.79%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 4.03x
- Recent ROE (10.55%) is below the historical average (13.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 13.27% | 32.30% | 0.09x | 4.41x | €214.87 Million |
| 2017 | 15.38% | 33.60% | 0.09x | 5.05x | €401.80 Million |
| 2018 | 13.46% | 31.47% | 0.09x | 4.70x | €347.36 Million |
| 2019 | 14.26% | 23.30% | 0.12x | 5.19x | €474.17 Million |
| 2020 | 14.06% | 20.50% | 0.14x | 4.95x | €504.85 Million |
| 2021 | 13.19% | 19.65% | 0.14x | 4.73x | €471.15 Million |
| 2022 | 12.55% | 16.47% | 0.15x | 4.92x | €398.36 Million |
| 2023 | 12.16% | 15.46% | 0.17x | 4.63x | €375.32 Million |
| 2024 | 11.16% | 15.40% | 0.16x | 4.56x | €218.58 Million |
| 2025 | 10.55% | 14.79% | 0.18x | 4.03x | €114.66 Million |
Industry Comparison
This section compares Genertec Universal Medical Group Company Limited's net assets metrics with peer companies in the Credit Services industry.
Industry Context
- Industry: Credit Services
- Average net assets among peers: $4,719,434,872
- Average return on equity (ROE) among peers: 1.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genertec Universal Medical Group Company Limited (5UM) | €25.04 Billion | 13.27% | 2.37x | $1.24 Billion |
| Yiren Digital Ltd (19YA) | $4.49 Billion | 25.74% | 1.15x | $102.03 Million |
| Qudian Inc (1QU) | $11.92 Billion | 27.38% | 0.54x | $283.31 Million |
| Yixin Group Limited (1YX) | $16.48 Billion | 4.91% | 1.95x | $1.15 Billion |
| TRUFIN PLC (29U) | $32.45 Million | -21.79% | 0.56x | $141.30 Million |
| 51 CREDIT CARD DL-00001 (2JY) | $709.57 Million | 1.56% | 0.64x | $93.38 Million |
| CREDIT CORP. GROUP LTD. (2RC) | $825.67 Million | 6.14% | 0.60x | $490.08 Million |
| HANHUA FNCL HLDG CO.H YC1 (5HF) | $7.97 Billion | 0.15% | 0.44x | $11.63 Million |
| HARMONEY CORP. LTD (6DR) | $39.84 Million | -33.12% | 20.51x | $40.54 Million |
| PREMIA FINANCE O.N. (81U) | $3.47 Million | 0.23% | 0.46x | $1.82 Million |
About Genertec Universal Medical Group Company Limited
Genertec Universal Medical Group Company Limited, together with its subsidiaries, provides financing, advisory, and medical services in the People's Republic of China. It operates through two segments, Finance Business and Healthcare Business. The Finance Business segment offers direct finance leasing; sale and leaseback; accounts receivable factoring; operating leases; and advisory services. Its… Read more